AT Bancorp decreased its position in CVS Health Corporation (NYSE:CVS) by 7.1% during the second quarter, Holdings Channel reports. The institutional investor owned 73,746 shares of the pharmacy operator’s stock after selling 5,662 shares during the period. CVS Health Corporation makes up about 1.0% of AT Bancorp’s holdings, making the stock its 20th largest position. AT Bancorp’s holdings in CVS Health Corporation were worth $7,061,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in CVS. State Street Corp boosted its stake in shares of CVS Health Corporation by 2.4% in the first quarter. State Street Corp now owns 44,552,112 shares of the pharmacy operator’s stock valued at $4,621,391,000 after buying an additional 1,023,799 shares in the last quarter. Nordea Investment Management AB boosted its stake in shares of CVS Health Corporation by 61.3% in the second quarter. Nordea Investment Management AB now owns 11,644,431 shares of the pharmacy operator’s stock valued at $1,114,838,000 after buying an additional 4,423,216 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of CVS Health Corporation by 0.9% in the first quarter. Geode Capital Management LLC now owns 8,917,040 shares of the pharmacy operator’s stock valued at $923,085,000 after buying an additional 77,690 shares in the last quarter. Legal & General Group Plc boosted its stake in shares of CVS Health Corporation by 1.9% in the first quarter. Legal & General Group Plc now owns 4,961,136 shares of the pharmacy operator’s stock valued at $514,632,000 after buying an additional 92,196 shares in the last quarter. Finally, UBS Asset Management Americas Inc. boosted its stake in shares of CVS Health Corporation by 1.9% in the second quarter. UBS Asset Management Americas Inc. now owns 4,856,007 shares of the pharmacy operator’s stock valued at $464,915,000 after buying an additional 91,148 shares in the last quarter. 80.96% of the stock is owned by institutional investors and hedge funds.

CVS Health Corporation (NYSE:CVS) traded up 0.12% on Friday, hitting $90.68. 1,855,398 shares of the company were exchanged. CVS Health Corporation has a 52-week low of $86.50 and a 52-week high of $106.67. The stock has a market cap of $96.68 billion, a PE ratio of 20.86 and a beta of 0.84. The firm has a 50 day moving average of $94.22 and a 200-day moving average of $97.87.

CVS Health Corporation (NYSE:CVS) last released its earnings results on Tuesday, August 2nd. The pharmacy operator reported $1.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.30 by $0.02. CVS Health Corporation had a net margin of 2.88% and a return on equity of 15.86%. The firm earned $43.70 billion during the quarter, compared to the consensus estimate of $44.28 billion. During the same period in the previous year, the firm earned $1.19 earnings per share. CVS Health Corporation’s revenue was up 17.6% compared to the same quarter last year. On average, equities analysts expect that CVS Health Corporation will post $5.86 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, November 3rd. Shareholders of record on Monday, October 24th will be given a dividend of $0.425 per share. This represents a $1.70 dividend on an annualized basis and a yield of 1.88%. CVS Health Corporation’s dividend payout ratio (DPR) is 39.08%.

Several analysts recently issued reports on CVS shares. Credit Suisse Group AG reaffirmed a “buy” rating and set a $115.00 price objective on shares of CVS Health Corporation in a research note on Sunday, June 5th. Leerink Swann reiterated a “buy” rating on shares of CVS Health Corporation in a report on Friday, June 10th. Morgan Stanley lowered shares of CVS Health Corporation from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $111.00 to $104.00 in a report on Monday, June 20th. Deutsche Bank AG boosted their target price on shares of CVS Health Corporation from $99.00 to $105.00 and gave the company a “hold” rating in a report on Wednesday, June 22nd. Finally, Mizuho reiterated a “buy” rating and issued a $108.00 target price (down from $117.00) on shares of CVS Health Corporation in a report on Thursday, June 23rd. Six research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $113.02.

CVS Health Corporation Company Profile

CVS Health Corporation, together with its subsidiaries, is a pharmacy company. The Company operates through three business segments: Pharmacy Services, Retail Pharmacy and Corporate. The Pharmacy Services segment provides a range of pharmacy benefit management (PBM) services and operates under the CVS/caremark Pharmacy Services, Novologix and Navarro Health Services names.

5 Day Chart for NYSE:CVS

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS).

Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with MarketBeat.com's FREE daily email newsletter.